Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. infection control specialists help prevent
Show results for
Products
Services
Training
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Infection Control Specialists Help Prevent Articles & Analysis

130 news found

Safeguarding Workers and Building Occupants from MRSA and Other Microbial Exposure Risks

Safeguarding Workers and Building Occupants from MRSA and Other Microbial Exposure Risks

Methicillin-resistant Staphylococcus aureus (MRSA) is described by the National Institute for Occupational Safety and Health (NIOSH) as a potentially dangerous type of staph bacteria. Staph, which is commonly carried on the skin or in the nose of healthy people, can sometimes cause infections, but most of these skin infections are minor. With MRSA, which is staph that is resistant to an ...

ByCochrane & Associates, LLC


International Infection Prevention Week and Resources to Protect People in Puerto Rico

International Infection Prevention Week and Resources to Protect People in Puerto Rico

International Infection Prevention Week (IIPW) has been championed by the Association for Professionals in Infection Control and Epidemiology since 1986. The annual event highlights the importance of infection prevention professionals and their efforts and control practices. These are crucial tasks as the Centers for Disease Control and Prevention (CDC) reports that on any given day, about 1 in ...

ByCochrane & Associates, LLC


International Infection Prevention Week and Resources to Protect Patients, Workers, and Building Occupants

International Infection Prevention Week and Resources to Protect Patients, Workers, and Building Occupants

The Association for Professionals in Infection Control and Epidemiology (APIC) has championed International Infection Prevention Week since 1986. For 2024, the annual event is taking place from October 13th to the 19th. International Infection Prevention Week highlights the importance of infection prevention professionals and their efforts and control practices. These are crucial tasks as the ...

ByCochrane & Associates, LLC


International Infection Prevention Week Discussed in New Online Video

International Infection Prevention Week Discussed in New Online Video

The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video today. Their newest production discusses International Infection Prevention Week (IIPW). “For 2024, IIPW is taking place from October 13th to the 19th,” said Paul Cochrane, President of Cochrane & Associates and the IAQ Video Network. “Infection prevention ...

ByCochrane & Associates, LLC


World MRSA Awareness Month Discussed in New Online Video

World MRSA Awareness Month Discussed in New Online Video

The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video today. Their newest production discusses World MRSA Awareness Month which takes place each October. “Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staph that can be resistant to several antibiotics,” said Paul Cochrane, President of Cochrane & ...

ByCochrane & Associates, LLC


CDC Offers Action Items to Reduce Infection Risks in Schools

CDC Offers Action Items to Reduce Infection Risks in Schools

In May, the Centers for Disease Control and Prevention (CDC) announced the release of new guidance for preventing the spread of infections in K-12 schools. The agency shared various everyday actions that schools can take to help keep students healthy by mitigating the spread of infections. The five actions listed by the CDC are: · Taking steps for cleaner air · ...

ByCochrane & Associates, LLC


Ace Therapeutics Announces Vaccine Development Services Against Superbugs

Ace Therapeutics Announces Vaccine Development Services Against Superbugs

Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, Ace Therapeutics announces its new vaccine development services to ...

ByAce Therapeutics


Comparison of the Rapid Bactericidal Efficacy of Commercially Available Surgical Solutions

Comparison of the Rapid Bactericidal Efficacy of Commercially Available Surgical Solutions

Introduction Intraoperative irrigation is a commonly used method aimed at reducing microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field prior to site closure.1 With the absence of universally established standard of care and robust clinical data, the selection of appropriate irrigation solution remains a topic of debate. Isotonic saline has ...

BySanara MedTech Inc.


Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens

Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens

An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for Disease Control and Prevention (CDC) ...

ByCochrane & Associates, LLC


Mitigating Exposure Risks to Mucormycetes to Protect Patients, Workers, and Building Occupants

Mitigating Exposure Risks to Mucormycetes to Protect Patients, Workers, and Building Occupants

Mucormycetes are a group of fungi that can cause a rare but serious fungal infection known as mucormycosis reports the Centers for Disease Control and Prevention (CDC). These fungi live in soil and decaying organic matter. People with a weakened immune system could get mucormycosis by inhaling fungal spores or if they enter the skin through an injury. Types of mucormycosis listed by CDC include: ...

ByCochrane & Associates, LLC


TOMI Secures Vizient Contract as an Approved Supplier of SteraMist Systems for Nationwide Healthcare Networks

TOMI Secures Vizient Contract as an Approved Supplier of SteraMist Systems for Nationwide Healthcare Networks

TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company has entered into a contract with Vizient, Inc. increasing TO Mi's presence in the U.S. healthcare system. Vizient is the largest group purchasing organization (GPO) in the healthcare industry supplying around $100 billion in ...

BySteraMist Disinfection


Protecting Patients, Workers and Building Occupants from Staphylococcus aureus and Other Pathogens in Puerto Rico

Protecting Patients, Workers and Building Occupants from Staphylococcus aureus and Other Pathogens in Puerto Rico

Staphylococcus aureus is a type of bacteria that has long been recognized as a cause of disease. Frequently referred to as staph, it is commonly found on the skin and hair, as well as in the nose and throat of people and animals. The Centers for Disease Control and Prevention (CDC) even reports that about 30% of people carry Staphylococcus aureus in their nose. Most of the time, staph does not ...

ByCochrane & Associates, LLC


Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection

Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection

As an expert in virology and microbiology, Creative Diagnostics recently introduced the Microneutralization Assay Service to support research labs in detecting virus-specific neutralizing antibodies from human and animal sera. Measuring antibody titers against specific viruses is indispensable to virology and several assays have been exploited based on similar principles, i.e., serial dilutions ...

ByCreative Diagnostics


TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2022 Financial Results on March 16, 2023

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2022 Financial Results on March 16, 2023

FREDERICK, Md., March 13, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the fourth quarter ended December 31, 2022, after the close of the financial markets on Thursday, March 16, 2023 and will hold a conference call at ...

BySteraMist Disinfection


TOMI to Attend Three Leading Pharmaceutical Conferences in the First Quarter of 2023

TOMI to Attend Three Leading Pharmaceutical Conferences in the First Quarter of 2023

FREDERICK, Md., Jan. 25, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that TOMI will present its SteraMist brand of products at three upcoming International Society for Pharmaceutical Engineering (ISPE) Conferences in the first quarter of 2023: The ISPE ...

BySteraMist Disinfection


TOMI Expands Globally with Purchase from National Health Services (NHS) Wales

TOMI Expands Globally with Purchase from National Health Services (NHS) Wales

FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain. NHS Wales is a publicly funded ...

BySteraMist Disinfection


7 December 2022 - FDA/CDC highlight need for infection preventions

7 December 2022 - FDA/CDC highlight need for infection preventions

Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for ...

ByDestiny Pharma plc


XF-73 Nasal Phase 3 development plans finalised

XF-73 Nasal Phase 3 development plans finalised

Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal. Highlights Discussions held ...

ByDestiny Pharma plc


Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections

Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...

ByLumen Bioscience, Inc.


XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID

XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID

Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...

ByDestiny Pharma plc

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT